Results 61 to 70 of about 8,906 (137)

Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial

open access: yesInternational Journal of Women's Health, 2013
Josep Lluis Carbonell Esteve,1 Rita Acosta,2 Yasmirian Pérez,2 Barbara Rodriguez,2 Isabel Seigler,2 Carlos Sanchez,2 Giuseppe Tomasi3 1Mediterránea Médica Clinic, Valencia, Spain; 2Eusebio Hernández Gynecology and Obstetrics ...
Esteve Carbonell JL   +6 more
doaj  

Reproductive outcomes following surgical removal of uterine fibroids

open access: yesМедицинский совет, 2019
The cohort prospective comparative study investigated the efficacy of mifepristone use in patients after surgical treatment of uterine myoma. It was shown that the use of mifepristone at a dose of 50 mg/day in a continuous mode for 3 months after ...
A. E. Mitichkin   +7 more
doaj   +1 more source

Profiling the host defense responses against Candida auris in a reliable Drosophila melanogaster infection model

open access: yesmLife, Volume 5, Issue 1, Page 51-67, February 2026.
Abstract The “superbug” Candida auris has been ranked as a priority fungal pathogen and is becoming a serious threat to public health. However, the underlying mechanisms of real‐world pathogen–host interactions remain elusive, in part due to the lack of powerful immunocompetent animal models.
Jie Li   +13 more
wiley   +1 more source

Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity

open access: yesCancer Cell International, 2009
Background The prototypical antiprogestin mifepristone exhibits potent growth inhibition activity towards ovarian cancer cells in vitro and in vivo.
Seidel Erin E   +3 more
doaj   +1 more source

Mifepristone and rapamycin have non-additive benefits for life span in mated female Drosophila

open access: yesFly
The drugs mifepristone and rapamycin were compared for their relative ability to increase the life span of mated female Drosophila melanogaster. Titration of rapamycin indicated an optimal concentration of approximately 50 μM, which increased median life
Gary N. Landis   +6 more
doaj   +1 more source

Pharmacokinetics and bioequivalence of two formulations of mifepristone tablets in healthy Chinese subjects under fasting conditions: a single-center, open, randomized, single-dose, double-period, two-sequence, crossover trial

open access: yesFrontiers in Pharmacology
ObjectiveA bioequivalence (BE) study was performed to evaluate the pharmacokinetics, safety, and bioequivalence of two formulations of mifepristone tablets in healthy Chinese volunteers under fasting conditions.MethodsA single-center, open, randomized ...
Yufeng Yan   +9 more
doaj   +1 more source

Advanced assessment of migration and invasion of cancer cells in response to mifepristone therapy using double fluorescence cytochemical labeling

open access: yesBMC Cancer, 2019
Background Previous work in our laboratory demonstrated that antiprogestin mifepristone impairs the growth and adhesion of highly metastatic cancer cells, and causes changes in their cellular morphology.
Sabrina J. Ritch   +3 more
doaj   +1 more source

Asoprisnil as a Novel Ligand Interacting with Stress-Associated Glucocorticoid Receptor

open access: yesBiomedicines
Background/objective: The glucocorticoid receptor (GR) is critical in regulating cortisol production during stress. This makes it a key target for treating conditions associated with hypothalamic–pituitary–adrenal (HPA) axis dysregulation, such as mental
Ovinuchi Ejiohuo   +3 more
doaj   +1 more source

Conditional Inhibition of Eip75B Eliminates the Effects of Mating and Mifepristone on Lifespan in Female Drosophila

open access: yesCells
Mating in female Drosophila melanogaster causes midgut hypertrophy and reduced lifespan, and these effects are blocked by the drug mifepristone. Eip75B is a transcription factor previously reported to have pleiotropic effects on Drosophila lifespan ...
Gary N. Landis   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy